1.1.3 High Cost Drugs - (Immunosuppressants)

High Cost Tariff Excluded Drugs - Immunosuppressants

For the Kent and Medway Health Economy National Tariff Excluded Drugs Manual
(HIGH COST DRUGS Page) Click Here

These drugs or devices are only commissioned for those indications listed under the individual drug. With regard to items commissioned by ICB, drugs or devices may not be commissioned across every ICB.

Etrasimod (Velsipity^®)

This High-Cost Drug has been approved for the following indications: -

For Gastro-intestinal Guidance & Information Page
Click Here

For treating moderately to severely active ulcerative colitis in people aged 16 and over as per NICE Guidance when:
•conventional or biological treatments cannot be tolerated or
•the condition has not responded well enough, or lost response to treatment.

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over NICE TA956
ICB commissioned - approval via Blueteq

Infliximab biosimilar (Flixabi^®)

This High-Cost Drug has been approved for the following indications: -

For Gastro-intestinal Guidance & Information Page
Click Here

For the treatment of Crohn's disease in adults as per NICE Guidance where:-
• disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments)
• or who are intolerant of or have contraindications to conventional therapy.

Infliximab and adalimumab for the treatment of Crohn's disease NICE TA187
ICB commissioned - approval via Blueteq

For for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years. as per NICE Guidance
• in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine or
• who cannot tolerate, or have medical contraindications for, such therapies.

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy NICE TA329
ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Paediatrics 6 - 17)

Mirikizumab (Omvoh^®)

This High-Cost Drug has been approved for the following indications: -

For Gastro-intestinal Guidance & Information Page
Click Here

For treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment as per NICE Guidance only if
• a tumour necrosis factor (TNF)‑alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment) or
• a TNF-alpha inhibitor cannot be tolerated or is not suitable

Mirikizumab for treating moderately to severely active ulcerative colitis NICE TA925
ICB commissioned - approval via Blueteq

Ozanimod (Zeposia^®)

This High-Cost Drug has been approved for the following indications: -

For Gastro-intestinal Guidance & Information Page
Click Here

Ozanimod for treating moderately to severely active ulcerative colitis in adults as per NICE Guidance only if:
• when conventional or biological treatments cannot be tolerated or are not working well enough, and infliximab is not suitable

Ozanimod for treating moderately to severely active ulcerative colitis NICE TA828
ICB commissioned - approval via Blueteq

Risankizumab - (Skyrizi^®)

This High-Cost Drug has been approved for the following indications: -

For Gastro-intestinal Guidance & Information Page
Click Here

For previously treated moderately to severely active Crohn's disease in people 16 years and over as per NICE Guidance only if:
• the disease has not responded well enough or lost response to a previous biological treatment, or
• a previous biological treatment was not tolerated, or
• tumour necrosis factor (TNF)-alpha inhibitors are not suitable.

Risankizumab for previously treated moderately to severely active Crohn's disease NICE Guidance TA888
ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Adolescents 16 - 17)

Upadacitinib (Rinvoq^®)

This High-Cost Drug has been approved for the following indications: -

For Gastro-intestinal Guidance & Information Page
Click Here

For treating moderately to severely active ulcerative colitis in adults as per NICE Guidance
• when conventional or biological treatment cannot be tolerated, or if the condition has not responded well enough or has stopped responding to these treatments as per NICE Guidance
•Treatment of previously treated moderately to severely active Crohn’s disease

Upadacitinib for treating moderately to severely active ulcerative colitis NICE Guidance TA856
ICB commissioned - approval via Blueteq

For treating moderately to severely active Crohn's disease in adults, as per NICE Guidance only if:
• the disease has not responded well enough or lost response to a previous biological treatment or
• a previous biological treatment was not tolerated or
• tumour necrosis factor (TNF)-alpha inhibitors are contraindicated

Upadacitinib for previously treated moderately to severely active Crohn’s disease NICE Guidance TA905
ICB commissioned - approval via Blueteq

First Line Choice
On Formulary
Specialist Initiation Only

Hospital Only
KMPT Initiation Only